CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
EP1345602B1
(de)
|
2000-11-30 |
2010-07-21 |
Novodermix International Limited |
Heilung von wunden
|
KR100883277B1
(ko)
*
|
2001-02-24 |
2009-02-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체 및 이의 제조방법
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
ATE423559T1
(de)
*
|
2001-04-04 |
2009-03-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
|
ES2258141T3
(es)
*
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1550668A4
(de)
*
|
2002-10-04 |
2008-10-01 |
Kissei Pharmaceutical |
Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt für dessen herstellung
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
KR20050090437A
(ko)
*
|
2003-01-03 |
2005-09-13 |
브리스톨-마이어스 스큅 컴퍼니 |
C-아릴 글루코시드 sglt2 억제제의 제조 방법
|
EP1457206A1
(de)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas
|
BRPI0408140B8
(pt)
|
2003-03-14 |
2018-12-11 |
Astellas Pharma Inc |
derivado de c-glicosídeo ou seu sal, composição farmacêutica e uso do derivado de c-glicosídeo ou seu sal
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
US8785403B2
(en)
*
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
EA009768B1
(ru)
*
|
2003-08-01 |
2008-04-28 |
Янссен Фармацевтика Нв |
Замещенные конденсированные гетероциклические с-гликозиды
|
TW200526678A
(en)
*
|
2003-08-01 |
2005-08-16 |
Janssen Pharmaceutica Nv |
Substituted indole-O-glucosides
|
AU2004261663A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
|
KR100778988B1
(ko)
*
|
2003-08-01 |
2007-11-28 |
다나베 미츠비시 세이야꾸 가부시키가이샤 |
나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
|
WO2005011592A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted indazole-o-glucosides
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005085265A1
(ja)
*
|
2004-03-04 |
2005-09-15 |
Kissei Pharmaceutical Co., Ltd. |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
CN103030617A
(zh)
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
CA2568640C
(en)
*
|
2004-06-04 |
2011-08-09 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing irbesartan
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
EP1773800A1
(de)
*
|
2004-07-27 |
2007-04-18 |
Boehringer Ingelheim International GmbH |
D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
EP1803729A4
(de)
*
|
2004-09-29 |
2008-10-01 |
Kissei Pharmaceutical |
1-(b-d-glycopyranosyl)-3-substituierte stickstoffhaltige heterocyclische verbindung, medizinische zusammensetzung, die diese enthält, und deren medizinische verwendung
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US20090036355A1
(en)
*
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
ES2314743T3
(es)
*
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
MY147375A
(en)
*
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
DE602006004964D1
(de)
*
|
2005-02-10 |
2009-03-12 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
WO2006089872A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
EP1874787B1
(de)
*
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituierte (heteroaryloxy-benzyl)-benzen-derivate als sglt-inhibitoren
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
ES2346347T3
(es)
*
|
2005-07-27 |
2010-10-14 |
Boehringer Ingelheim International Gmbh |
Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
|
CA2617102A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EP1924571B1
(de)
*
|
2005-08-30 |
2010-10-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
MX2008002457A
(es)
*
|
2005-09-08 |
2008-04-07 |
Boehringer Ingelheim Int |
Formas cristalinas de 1-cloro-4-(??-d-clucopiranos-1-il).
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
BRPI0620718A2
(pt)
*
|
2005-10-28 |
2011-11-22 |
Takeda Pharmaceutical |
agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
|
AU2007216452A1
(en)
|
2006-02-15 |
2007-08-23 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CN101437823B
(zh)
|
2006-05-04 |
2014-12-10 |
勃林格殷格翰国际有限公司 |
多晶型
|
WO2007143052A1
(en)
*
|
2006-06-01 |
2007-12-13 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
WO2008020011A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
EP2066344B2
(de)
*
|
2006-09-07 |
2016-06-29 |
GlaxoSmithKline Biologicals S.A. |
Inaktiviertes Poliovirus Mischimpfstoff
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
WO2008044762A1
(fr)
|
2006-10-13 |
2008-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
|
EP2086991A1
(de)
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
Kristalline form von 4-(?-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)benzyl]benzol, verfahren zu deren herstellung und deren verwendung zur herstellung von medikamenten
|
CN101611032B
(zh)
*
|
2006-12-04 |
2012-07-18 |
詹森药业有限公司 |
作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
CN101657471B
(zh)
|
2006-12-06 |
2013-07-03 |
史密丝克莱恩比彻姆公司 |
二环化合物及其作为抗糖尿病药的用途
|
WO2008075736A1
(ja)
*
|
2006-12-21 |
2008-06-26 |
Astellas Pharma Inc. |
C-グリコシド誘導体の製造方法及びその合成中間体
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
KR101663324B1
(ko)
*
|
2007-07-26 |
2016-10-06 |
렉시컨 파마슈티컬스 인코퍼레이티드 |
나트륨 글루코스 공-전달체 2 억제제의 제조에 유용한 방법 및 화합물
|
CL2008002425A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
CN101784278A
(zh)
*
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
ES2654894T3
(es)
*
|
2007-08-23 |
2018-02-15 |
Theracos Sub, Llc |
Derivados de (2S,3R,4R,5S,6R)-2-(4-cloro-3-bencilfenil)-6-(hidroximetil)tetrahidro-2H-piran-3,4,5-triol para su uso en el tratamiento de diabetes
|
PT2200606T
(pt)
*
|
2007-09-10 |
2017-12-13 |
Janssen Pharmaceutica Nv |
Processo para a preparação de compostos úteis como inibidores de sglt
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
PE20091211A1
(es)
*
|
2007-11-30 |
2009-09-14 |
Boehringer Ingelheim Int |
Derivados de pirazolopirimidina como moduladores de pde9a
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
CN101969944B
(zh)
*
|
2008-01-31 |
2013-04-10 |
安斯泰来制药有限公司 |
脂肪性肝病的治疗用医药组合物
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
JP5820269B2
(ja)
*
|
2008-05-22 |
2015-11-24 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
|
WO2009143021A1
(en)
*
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
CA2730734C
(en)
*
|
2008-07-15 |
2017-04-25 |
Theracos, Inc. |
Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
JP5906086B2
(ja)
*
|
2008-08-15 |
2016-04-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患の治療に用いるためのプリン誘導体
|
KR101654231B1
(ko)
*
|
2008-08-22 |
2016-09-05 |
테라코스 서브, 엘엘씨 |
Sglt2 억제제의 제조방법
|
AU2009286380B2
(en)
*
|
2008-08-28 |
2011-09-15 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
WO2010026214A1
(en)
|
2008-09-08 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Pyrazolopyrimidines and their use for the treatment of cns disorders
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
CN102159561A
(zh)
*
|
2008-09-19 |
2011-08-17 |
诺瓦提斯公司 |
糖苷衍生物及其用途
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
WO2010045656A2
(en)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
KR20110103968A
(ko)
|
2008-12-23 |
2011-09-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
유기 화합물의 염 형태
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
MY161472A
(en)
|
2009-02-13 |
2017-04-14 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
LT2395983T
(lt)
*
|
2009-02-13 |
2020-07-10 |
Boehringer Ingelheim International Gmbh |
Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
WO2010092126A1
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
US8466113B2
(en)
*
|
2009-02-23 |
2013-06-18 |
Taisho Pharmaceutical Co., Ltd. |
4-isopropylphenyl glucitol compounds as SGLT1 inhibitors
|
EP2226076A1
(de)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
|
AP2011005819A0
(en)
*
|
2009-03-31 |
2011-08-31 |
Boehringer Ingelheim Int |
1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
|
EP2435033A1
(de)
*
|
2009-05-27 |
2012-04-04 |
Bristol-Myers Squibb Company |
Verfahren zur behandlung von diabetes typ 2 bei patienten, die gegen frühere behandlungen mit anderen antidiabetika resistent waren, unter verwendung eines sglt2-inhibitors und zusammensetzungen davon
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
AU2010270202B2
(en)
|
2009-07-10 |
2014-04-24 |
Janssen Pharmaceutica Nv |
Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
DK2486029T3
(en)
*
|
2009-09-30 |
2015-08-24 |
Boehringer Ingelheim Int |
Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
|
CA2775961C
(en)
*
|
2009-09-30 |
2017-11-07 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
US10610489B2
(en)
*
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
RS55909B1
(sr)
*
|
2009-10-14 |
2017-09-29 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
AU2010310956B2
(en)
|
2009-11-02 |
2014-05-08 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
EP2498759B1
(de)
|
2009-11-13 |
2018-08-01 |
AstraZeneca AB |
Tablettenformulierungen mit sofortiger freisetzung
|
RU2712757C3
(ru)
|
2009-11-13 |
2021-06-09 |
Астразенека Аб |
Композиция двухслойной таблетки
|
WO2011058193A1
(en)
|
2009-11-16 |
2011-05-19 |
Mellitech |
[1,5]-diazocin derivatives
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
BR112012028136A2
(pt)
|
2010-05-05 |
2016-08-09 |
Boehringer Ingelheim Int |
terapia de combinaçao
|
TWI564034B
(zh)
|
2010-05-11 |
2017-01-01 |
田邊三菱製藥股份有限公司 |
含1-(β-D-葡萄吡喃糖苷)-3-(苯基噻吩基甲基)苯化合物之錠劑
|
CN102883726A
(zh)
|
2010-05-11 |
2013-01-16 |
詹森药业有限公司 |
包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物作为SGLT抑制剂的药物制剂
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
AP2012006631A0
(en)
|
2010-08-12 |
2012-12-31 |
Boehringer Ingelheim Int |
6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
EP2611442B1
(de)
|
2010-09-03 |
2018-07-04 |
Bristol-Myers Squibb Company |
Wirkstoffformulierungen mit waserlöslichen antioxidanzien
|
US8921328B2
(en)
|
2010-09-14 |
2014-12-30 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
RU2607480C2
(ru)
|
2011-02-01 |
2017-01-10 |
Бристол-Майерс Сквибб Компани |
Фармацевтические композиции, содержащие аминосоединение
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
CN103965176B
(zh)
|
2011-02-18 |
2016-03-16 |
凯惠药业(上海)有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
AU2012248061C1
(en)
*
|
2011-04-25 |
2016-07-14 |
Beijing Prelude Pharm. Sci. & Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
RU2603769C2
(ru)
*
|
2011-05-26 |
2016-11-27 |
Тфшем |
Семейство арил, гетероарил, о-арил и о-гетероарил карбасахаров
|
ES2448398T3
(es)
|
2011-06-03 |
2014-03-13 |
Ratiopharm Gmbh |
Composición farmacéutica que comprende dapagliflozina y ciclodextrina
|
MX2013014135A
(es)
|
2011-06-03 |
2014-01-23 |
Boehringer Ingelheim Int |
Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
|
CA2837232A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
CN102875503B
(zh)
|
2011-06-25 |
2016-05-25 |
山东轩竹医药科技有限公司 |
C-糖苷衍生物
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP2731947B1
(de)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes
|
JP2014530186A
(ja)
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
CN103889429B
(zh)
*
|
2011-10-31 |
2016-10-19 |
台湾神隆股份有限公司 |
Sglt2抑制剂的结晶和非结晶形式
|
EP2597090A1
(de)
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Kristallines Dapagliflozinhydrat
|
SI2794626T1
(en)
|
2011-12-22 |
2018-02-28 |
Glycomimetics, Inc. |
E-SELECTINE ANTAGONIST COMPOUNDS
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013178064A1
(zh)
*
|
2012-05-29 |
2013-12-05 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(de)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
BR112015004012A2
(pt)
*
|
2012-08-30 |
2017-07-04 |
Taisho Pharmaceutical Co Ltd |
combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
|
AU2013355238B2
(en)
|
2012-12-07 |
2017-12-14 |
Glycomimetics, Inc. |
Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9573959B2
(en)
|
2013-03-14 |
2017-02-21 |
Msd International Gmbh |
Methods for preparing SGLT2 inhibitors
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
PL2981269T3
(pl)
|
2013-04-04 |
2024-02-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt koniowatych
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HUE041709T2
(hu)
|
2013-04-05 |
2019-05-28 |
Boehringer Ingelheim Int |
Az empagliflozin terápiás alkalmazásai
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
DK2986304T3
(da)
|
2013-04-18 |
2022-04-04 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
|
WO2014178040A1
(en)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-crystals of dapagliflozin
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
US20160214953A1
(en)
|
2013-09-23 |
2016-07-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of dapagliflozin
|
EP3049397A1
(de)
*
|
2013-09-27 |
2016-08-03 |
Sun Pharmaceutical Industries Ltd |
Verfahren zur reinigung von dapagliflozin
|
JP6450769B2
(ja)
|
2013-09-27 |
2019-01-09 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
グルコピラノシル誘導体及びその医薬品における使用
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
WO2015063726A1
(en)
|
2013-10-31 |
2015-05-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
MX2016007856A
(es)
|
2013-12-17 |
2016-10-07 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabolicos en animales felinos.
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
CN104761522B
(zh)
*
|
2014-01-03 |
2017-02-15 |
山东轩竹医药科技有限公司 |
光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
KR102414283B1
(ko)
|
2014-01-23 |
2022-06-29 |
베링거잉겔하임베트메디카게엠베하 |
개과 동물에서 대사 장애의 치료
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(de)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
US20170056365A1
(en)
|
2014-02-28 |
2017-03-02 |
Sun Pharmaceutical Industries Limited |
Dapagliflozin compositions
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
US20170029398A1
(en)
*
|
2014-03-06 |
2017-02-02 |
Srinivasan Thirumalai Rajan |
Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
|
EP3125882B1
(de)
|
2014-04-01 |
2020-05-13 |
Boehringer Ingelheim Vetmedica GmbH |
Behandlung metabolischer störungen bei einhufern
|
CN105001213B
(zh)
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
US20170135981A1
(en)
*
|
2014-05-16 |
2017-05-18 |
Astrazeneca Ab |
Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
WO2015198227A1
(en)
|
2014-06-23 |
2015-12-30 |
Sun Pharmaceutical Industries Limited |
Co-crystal of dapagliflozin with citric acid
|
CN106714840A
(zh)
|
2014-09-25 |
2017-05-24 |
阿斯利康(瑞典)有限公司 |
用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
AU2015355136B2
(en)
|
2014-12-03 |
2020-06-25 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
US10508128B2
(en)
|
2015-02-09 |
2019-12-17 |
Indoco Remedies Limited |
Process for the preparation of SGLT inhibitor compounds
|
WO2016144862A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
WO2016161995A1
(en)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Solid forms of amorphous dapagliflozin
|
US10556877B2
(en)
|
2015-05-05 |
2020-02-11 |
Glenmark Life Sciences Limited |
Process for preparation of dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
ES2896101T3
(es)
|
2015-09-15 |
2022-02-23 |
Laurus Labs Ltd |
Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
US20170106009A1
(en)
|
2015-10-15 |
2017-04-20 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
HUE051212T2
(hu)
*
|
2016-01-04 |
2021-03-01 |
Jeil Pharmaceutical Co Ltd |
Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
|
WO2017118945A1
(en)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Premix of dapagliflozin and process for the preparation thereof
|
US11045485B2
(en)
|
2016-01-22 |
2021-06-29 |
Glycomimetics, Inc. |
Glycomimetic inhibitors of PA-IL and PA-IIL lectins
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
EP3435987A1
(de)
|
2016-03-31 |
2019-02-06 |
Lupin Limited |
Pharmazeutische zusammensetzung aus dapagliflozin
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
EP3466939B1
(de)
*
|
2016-05-24 |
2021-02-24 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Neue dapagliflozinkristallform der und herstellungsverfahren und verwendung davon
|
WO2017203229A1
(en)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Dapagliflozin premixes
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
EP3497131B1
(de)
|
2016-08-08 |
2022-03-09 |
GlycoMimetics, Inc. |
Kombination von t-zell-checkpoint-inhibitoren mit e-selectin- oder cxcr4-inhibitoren oder mit heterobifunktionellen e-selectin- wie auch cxcr4-inhibitoren
|
US11427555B2
(en)
*
|
2016-08-09 |
2022-08-30 |
Laurus Labs Limited |
Processes for preparation of dapagliflozin or its solvates or co-crystals thereof
|
WO2018029264A1
(en)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Process for preparation of dapagliflozin and intermediates thereof
|
BR112019006642A2
(pt)
|
2016-10-07 |
2019-07-02 |
Glycomimetics Inc |
antagonistas multiméricos de e-selectina altamente potentes
|
EA201990951A1
(ru)
|
2016-10-19 |
2019-11-29 |
|
Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Process for the preparation of dapagliflozin
|
JP7272956B2
(ja)
|
2017-03-15 |
2023-05-12 |
グリコミメティクス, インコーポレイテッド |
E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体
|
WO2018167589A1
(en)
|
2017-03-16 |
2018-09-20 |
Inventia Healthcare Private Limited |
Pharmaceutical composition comprising dapagliflozin
|
EP3606527A1
(de)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma-agonist zur behandlung der progressiven supranuklearen blickparese
|
CN110869380A
(zh)
*
|
2017-05-09 |
2020-03-06 |
皮拉马尔企业有限公司 |
用于制备sglt2抑制剂和其中间体的方法
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
WO2019108750A1
(en)
|
2017-11-30 |
2019-06-06 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
WO2019133878A1
(en)
|
2017-12-29 |
2019-07-04 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
BR112020018184A2
(pt)
|
2018-03-05 |
2021-02-02 |
Glycomimetics, Inc. |
usos de compostos
|
JP2021520394A
(ja)
|
2018-04-17 |
2021-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、処置方法及びその使用
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(en)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
A novel process for the preparation of sglt-2 inhibitors
|
KR20200005320A
(ko)
|
2018-07-06 |
2020-01-15 |
한미약품 주식회사 |
무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
|
PE20210644A1
(es)
*
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
JP2022530575A
(ja)
|
2019-08-30 |
2022-06-30 |
アストラゼネカ・アクチエボラーグ |
ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
|
UY38969A
(es)
*
|
2019-11-28 |
2021-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
|
KR20220143732A
(ko)
|
2020-02-17 |
2022-10-25 |
베링거잉겔하임베트메디카게엠베하 |
고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
|
CA3169665A1
(en)
|
2020-02-21 |
2021-08-26 |
Zaklady Farmaceutyczne Polpharma S.A. |
Pharmaceutical composition comprising dapagliflozin
|
EP4114365A1
(de)
|
2020-03-05 |
2023-01-11 |
KRKA, d.d., Novo mesto |
Pharmazeutische zusammensetzung mit sglt2-inhibitor
|
CA3173808A1
(en)
|
2020-03-06 |
2021-09-10 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
JP2023523596A
(ja)
|
2020-04-22 |
2023-06-06 |
バイエル アクチェンゲゼルシャフト |
心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
CN115867538A
(zh)
|
2020-06-05 |
2023-03-28 |
新梅斯托克公司 |
高纯的无定形达格列净的制备
|
WO2021260617A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
An improved process for preparation of dapagliflozin propanediol monohydrate
|
BR112023000406A2
(pt)
|
2020-07-10 |
2023-01-31 |
Astrazeneca Ab |
Combinação de zibotentan e dapagliflozina
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
WO2022067724A1
(zh)
|
2020-09-30 |
2022-04-07 |
北京睿创康泰医药研究院有限公司 |
一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
|
WO2022119543A1
(en)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
EP4315350A1
(de)
|
2021-04-01 |
2024-02-07 |
AstraZeneca UK Limited |
Systeme und verfahren zur verwaltung von prädiabetes mit einer pharmazeutischen gliflozin-natrium-glucose-cotransport-2-inhibitorzusammensetzung
|
EP4079296A1
(de)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Zweischichtige tablettenformulierung mit amorphem dapagliflozin und metformin
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
AU2022319909A1
(en)
|
2021-07-28 |
2024-02-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
WO2023006747A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
EP4212150A1
(de)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Zweischichtige tablettenzusammensetzung mit amorphem dapagliflozin und metformin
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2023237512A1
(en)
|
2022-06-07 |
2023-12-14 |
Astrazeneca Ab |
Combinations of rxfp1 modulators and sglt2 inhibitors
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|